Cargando…

The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation

BACKGROUND: This study aimed to analyze associations between genetic variants and plasma concentrations along with clinical outcomes in dabigatran in patients with non-valvular atrial fibrillation (NVAF). METHODS: We conducted a prospective study and enrolled NVAF patients treated with dabigatran in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhu, Qian, Chenyue, Su, Cunjing, Tao, Hong, Mao, Jiaojiao, Guo, Zhening, Zhu, Xinyi, Pan, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652877/
https://www.ncbi.nlm.nih.gov/pubmed/36368930
http://dx.doi.org/10.1186/s12872-022-02910-4
_version_ 1784828570487488512
author Zhu, Zhu
Qian, Chenyue
Su, Cunjing
Tao, Hong
Mao, Jiaojiao
Guo, Zhening
Zhu, Xinyi
Pan, Jie
author_facet Zhu, Zhu
Qian, Chenyue
Su, Cunjing
Tao, Hong
Mao, Jiaojiao
Guo, Zhening
Zhu, Xinyi
Pan, Jie
author_sort Zhu, Zhu
collection PubMed
description BACKGROUND: This study aimed to analyze associations between genetic variants and plasma concentrations along with clinical outcomes in dabigatran in patients with non-valvular atrial fibrillation (NVAF). METHODS: We conducted a prospective study and enrolled NVAF patients treated with dabigatran in the real world. A total of 86 patients treated with 110 mg DE twice daily were recruited for this study. Blood samples were obtained from each patient and used for genotyping and determination of plasma dabigatran concentration. All bleeding and thromboembolic complications were recorded during the 1.5 years of follow-up. RESULTS: Eighty-three patients provided samples at the trough plasma level of dabigatran, and 58 patients provided samples at the peak plasma level of dabigatran. There was a significant association between the CES1 SNP rs8192935 and trough plasma concentrations of dabigatran (P = 0.013). Our results showed that the CES1 SNP rs8192935 significantly influenced dabigatran trough concentrations in the Chinese population, and carriers of the G allele had increased trough plasma concentrations of dabigatran compared to noncarriers. The ABCB1 SNP c.2482-2236G > A (rs4148738) was associated with major bleeding events in the addictive model (P = 0.046, OR = 3.29) and dominant model (P = 0.040, OR = 8.17). Additionally, the ABCB1 SNP c.3435 C > T (rs1045642) was associated with the incidence of major bleeding events in the addictive model (P = 0.043, OR = 3.34) and dominant model (P = 0.046, OR = 7.77). However, no significant associations were found between all the SNPs and the incidence of minor bleeding events. CONCLUSION: Our results indicated that the CES1 polymorphism rs8192935 was associated with trough plasma concentrations of dabigatran. Carriers of the G allele had increased trough plasma concentrations of dabigatran compared to noncarriers. The ABCB1 polymorphisms rs4148738 and rs1045642 were associated with an increased risk for major bleeding events for the first time in a Chinese population.
format Online
Article
Text
id pubmed-9652877
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96528772022-11-15 The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation Zhu, Zhu Qian, Chenyue Su, Cunjing Tao, Hong Mao, Jiaojiao Guo, Zhening Zhu, Xinyi Pan, Jie BMC Cardiovasc Disord Research BACKGROUND: This study aimed to analyze associations between genetic variants and plasma concentrations along with clinical outcomes in dabigatran in patients with non-valvular atrial fibrillation (NVAF). METHODS: We conducted a prospective study and enrolled NVAF patients treated with dabigatran in the real world. A total of 86 patients treated with 110 mg DE twice daily were recruited for this study. Blood samples were obtained from each patient and used for genotyping and determination of plasma dabigatran concentration. All bleeding and thromboembolic complications were recorded during the 1.5 years of follow-up. RESULTS: Eighty-three patients provided samples at the trough plasma level of dabigatran, and 58 patients provided samples at the peak plasma level of dabigatran. There was a significant association between the CES1 SNP rs8192935 and trough plasma concentrations of dabigatran (P = 0.013). Our results showed that the CES1 SNP rs8192935 significantly influenced dabigatran trough concentrations in the Chinese population, and carriers of the G allele had increased trough plasma concentrations of dabigatran compared to noncarriers. The ABCB1 SNP c.2482-2236G > A (rs4148738) was associated with major bleeding events in the addictive model (P = 0.046, OR = 3.29) and dominant model (P = 0.040, OR = 8.17). Additionally, the ABCB1 SNP c.3435 C > T (rs1045642) was associated with the incidence of major bleeding events in the addictive model (P = 0.043, OR = 3.34) and dominant model (P = 0.046, OR = 7.77). However, no significant associations were found between all the SNPs and the incidence of minor bleeding events. CONCLUSION: Our results indicated that the CES1 polymorphism rs8192935 was associated with trough plasma concentrations of dabigatran. Carriers of the G allele had increased trough plasma concentrations of dabigatran compared to noncarriers. The ABCB1 polymorphisms rs4148738 and rs1045642 were associated with an increased risk for major bleeding events for the first time in a Chinese population. BioMed Central 2022-11-11 /pmc/articles/PMC9652877/ /pubmed/36368930 http://dx.doi.org/10.1186/s12872-022-02910-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhu, Zhu
Qian, Chenyue
Su, Cunjing
Tao, Hong
Mao, Jiaojiao
Guo, Zhening
Zhu, Xinyi
Pan, Jie
The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation
title The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation
title_full The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation
title_fullStr The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation
title_full_unstemmed The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation
title_short The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation
title_sort impact of abcb1 and ces1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652877/
https://www.ncbi.nlm.nih.gov/pubmed/36368930
http://dx.doi.org/10.1186/s12872-022-02910-4
work_keys_str_mv AT zhuzhu theimpactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT qianchenyue theimpactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT sucunjing theimpactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT taohong theimpactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT maojiaojiao theimpactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT guozhening theimpactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT zhuxinyi theimpactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT panjie theimpactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT zhuzhu impactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT qianchenyue impactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT sucunjing impactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT taohong impactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT maojiaojiao impactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT guozhening impactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT zhuxinyi impactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation
AT panjie impactofabcb1andces1polymorphismsonthesafetyofdabigatraninpatientswithnonvalvularatrialfibrillation